NCT05273619

Efficacy and Safety of XC8, Film-coated Tablets, 40 mg in Patients With Dry Non-productive Cough Against Acute Respiratory Viral Infection

Double-blind Placebo-controlled Multicenter Randomized Clinical Trial to Assess Efficacy and Safety of XC8, Film-coated Tablets, 40 mg in Patients With Dry Non-productive Cough Against Acute Respiratory Viral Infection

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 250 (actual)
• Sponsor: Valenta Pharm JSC · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

Study to assess the efficacy and safety of XC8, film-coated tablets, 10 mg in comparison with placebo in patients with dry non-productive cough against acute respiratory infection.

Conditions

• Common Cold
• Acute Respiratory Infection
• Influenza, Human

Interventions

Type	Name	Description
DRUG	XC8, film-coated tablets, 10 mg	80 mg/day: 4 tablets (40 mg) twice a day
DRUG	Placebo	4 tablets twice a day

Timeline

• Start date: 2022-05-23
• Primary completion: 2022-07-13
• Completion: 2022-07-29
• First posted: 2022-03-10
• Last updated: 2023-07-27

Locations

6 sites across 1 country: Russia